Title :

Two cases of rare late onset life-threatening pseudoprogression with immune check point inhibitors in advanced cancer patients - a case report

Author(s) :

Coudert, Valentin [Auteur]
Robin, Yves-Marie [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Tessier, Williams [Auteur]
Forestier, Alexandra [Auteur]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Journal title :

Acta Oncologica

Abbreviated title :

Acta Oncol

Pages :

1-4

Publisher :

Taylor & Francis

Publication date :

2021-02-13

ISSN :

1651-226X

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Introduction Administration of immune checkpoint inhibitors (ICIs) induces different patterns of response, including the classical complete or partial response and disease progression and new patterns such as hyperprogressionand ...
Show more >Introduction Administration of immune checkpoint inhibitors (ICIs) induces different patterns of response, including the classical complete or partial response and disease progression and new patterns such as hyperprogressionand pseudoprogression. Pseudoprogression is defined as an increase in tumor size followed by a response to treatment, resulting from an exacerbated immune cell infiltration in the tumor bed, including CD103+ and CD8+ cells [Citation1]. Pseudoprogression is a rare phenomenon, with a rate not exceeding 10% in patients treated with ICI [Citation2]. In everyday practice, the misclassification of pseudoprogression as disease progression remains a concern. According to iRECIST guidelines, confirmation of the progression with later imaging is mandatory to make sure that the 'unconfirmed' progression is 'disease progression' and not 'pseudoprogression' [Citation3]. Hodi et al. [Citation4] described that pseudoprogression occurs more often at the beginning of ICI treatment. Here, we report two cases of dramatic pseudoprogression occurring 36 and 10 months after the initiation of ICI.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
INSERM
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
• Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Submission date :

2022-06-15T13:58:07Z
2024-03-20T10:15:10Z